Genetics Analysis Services for Brain Tumors

The occurrence of brain tumors is influenced by a combination of genetic and environmental factors. A small percentage of brain tumors occur in individuals with a family history of brain tumors or a family history of genetic syndromes. This genetic trait usually increases the risk of developing brain tumors in a particular population. Mutations in brain tumor susceptibility genes increase an individual's risk of developing brain tumors to some extent.

Genetic analysis services we offer for brain tumors

Alfa Cytology uses brain tumor genetic testing to detect multiple genetic brain tumor susceptibility genes and analyze their mutation information. We can also assess the relative risk of brain tumor development by combining existing mutations with the relationship between the genes and brain tumorigenesis.

Epigenetic analysis service for brain tumor samples

The study of epigenetic changes (such as aberrant methylation and altered transcription factor binding) can provide insight into important oncogenic pathways. Methylation changes often activate or silence genes, and epigenomic changes can affect gene expression and the rate of brain tumor progression. We use next-generation sequencing (NGS) and microarray technology (methylation microarrays) to detect methylation patterns and other epigenetic changes in brain tumors to meet the rapidly changing needs of the brain tumor research field.

Structural alterations and single base mutation analysis service

• Translocations, loss of heterozygosity (LOH) and copy number variants (CNV) can all have an impact on brain tumor susceptibility. Single nucleotide polymorphisms (SNPs) are useful biomarkers for identifying genomic regions associated with brain tumors.
• We apply NGS technology to provide high sensitivity, accuracy, and comprehensiveness in the identification of cellular variants in brain tumor samples. We have excellent performance in both exome capture and targeted gene combination capture.

Rare gene mutation detection service

• Brain tumors can be caused by rare mutations, which can be as low as 0.1% or less in allele frequency and can exhibit significant genetic heterogeneity. We offer targeted sequence capture for sensitive and accurate detection of rare mutations in brain tumor samples.
• Our combination of amplicon-based technology and targeted sequence capture sequencing gives accurate results even with a wide variety of genes and very low starting DNA. With the help of molecular barcoding, errors due to objective factors in high coverage NGS data can be identified and eliminated.

Intratumor genetic heterogeneity analysis service

We collect brain tumor tissue samples to generate muta-genomic data for each tissue sample and calculate a combinatorial index of genetic heterogeneity within the brain tumor based on the muta-genomic data. This serves as an indicator of genetic heterogeneity within brain tumors and provides a quantitative tool for stratified analysis of brain tumor patients.

Brain tumor genetic risk assessment service

We provide comprehensive genetic testing and genetic counseling services to help our clients understand how genetic factors may affect their own and their relatives' risk of developing brain tumors.

• We can test for a wide range of genes, allowing for full scans of key brain tumor genes. One sample, one test, screens for all exon sequences of genetic susceptibility genes for brain tumors.
• We utilize the NGS sequencing platform to comprehensively evaluate multiple variants of genes such as SNP and InDel at one time, with a high average effective sequencing depth and more accurate test results.

Alfa Cytology focuses on the detection and analysis of the genetic risk of brain tumors, which will help more researchers to detect the risk of brain tumors in patients at an early stage so that early treatment can be done. Please contact our staff for the latest protocols.